loader
Please Wait
Applying Filters...

Euroapi Company Header Euroapi Company Header

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Technical details about Vidofludimus calcium anhydrous, learn more about the structure, uses, toxicity, action, side effects and more

    Client Email Product
    Menu

    Vidofludimus calcium anhydrous

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass

    Farmhispania Group, a leading European CDMO in HPAPI Technologies & High Potency Fermentation.

    One Pharma aims to be one of the leading generic companies in Europe.

    2D Structure
    1. Also known as: Fw5vy7926x, 1-cyclopentene-1-carboxylic acid, 2-(((3-fluoro-3'-methoxy(1,1'-biphenyl)-4-yl)amino)carbonyl)-, calcium salt (2:1), 1354012-90-0, Unii-fw5vy7926x, Vidofludimus calcium [who-dd]
    Molecular Formula
    C40H34CaF2N2O8
    Molecular Weight
    748.8  g/mol
    InChI Key
    KWSJBFAXOPFZSO-UHFFFAOYSA-L
    FDA UNII
    FW5VY7926X
    Vidofludimus Calcium Anhydrous is the calcium salt form of vidofludimus, an orally bioavailable inhibitor of dihydroorotate dehydrogenase (DHODH), with potential anti-inflammatory, immunomodulating and anti-viral activities. Upon administration, vidofludimus specifically targets, binds to and prevents the activation of DHODH. This prevents the fourth enzymatic step in de novo pyrimidine synthesis, leading to inhibition of transcriptional elongation, cell cycle arrest, and apoptosis in activated lymphocytes. DHODH inhibition also leads to metabolic stress in activated lymphocytes and inhibition of the release of proinflammatory cytokines including interleukin (IL)-17 (IL-17A and IL-17F) and interferon-gamma (IFNg), thereby reducing inflammation. In addition, DHODH inhibition may lead to host-based anti-viral activity against many viruses. DHODH, a mitochondrial enzyme that catalyzes the conversion of dihydroorotate (DHO) to orotate, is a key enzyme in pyrimidine de novo biosynthesis. Metabolically highly activated and rapidly proliferating lymphocytes and various virus infected cells require de novo synthesis to meet their needs for pyrimidines.
    1 2D Structure

    2D Structure

    2 Identification
    2.1 Computed Descriptors
    2.1.1 IUPAC Name
    calcium;2-[[2-fluoro-4-(3-methoxyphenyl)phenyl]carbamoyl]cyclopentene-1-carboxylate
    2.1.2 InChI
    InChI=1S/2C20H18FNO4.Ca/c2*1-26-14-5-2-4-12(10-14)13-8-9-18(17(21)11-13)22-19(23)15-6-3-7-16(15)20(24)25;/h2*2,4-5,8-11H,3,6-7H2,1H3,(H,22,23)(H,24,25);/q;;+2/p-2
    2.1.3 InChI Key
    KWSJBFAXOPFZSO-UHFFFAOYSA-L
    2.1.4 Canonical SMILES
    COC1=CC=CC(=C1)C2=CC(=C(C=C2)NC(=O)C3=C(CCC3)C(=O)[O-])F.COC1=CC=CC(=C1)C2=CC(=C(C=C2)NC(=O)C3=C(CCC3)C(=O)[O-])F.[Ca+2]
    2.2 Other Identifiers
    2.2.1 UNII
    FW5VY7926X
    2.3 Synonyms
    2.3.1 Depositor-Supplied Synonyms

    1. Fw5vy7926x

    2. 1-cyclopentene-1-carboxylic Acid, 2-(((3-fluoro-3'-methoxy(1,1'-biphenyl)-4-yl)amino)carbonyl)-, Calcium Salt (2:1)

    3. 1354012-90-0

    4. Unii-fw5vy7926x

    5. Vidofludimus Calcium [who-dd]

    2.4 Create Date
    2012-04-23
    3 Chemical and Physical Properties
    Molecular Weight 748.8 g/mol
    Molecular Formula C40H34CaF2N2O8
    Hydrogen Bond Donor Count2
    Hydrogen Bond Acceptor Count10
    Rotatable Bond Count8
    Exact Mass748.1909132 g/mol
    Monoisotopic Mass748.1909132 g/mol
    Topological Polar Surface Area157 Ų
    Heavy Atom Count53
    Formal Charge0
    Complexity571
    Isotope Atom Count0
    Defined Atom Stereocenter Count0
    Undefined Atom Stereocenter Count0
    Defined Bond Stereocenter Count0
    Undefined Bond Stereocenter Count0
    Covalently Bonded Unit Count3
    Post Enquiry
    POST ENQUIRY